ABSTRACT
Initially synthesized in 1957 as a pyrimidine antagonist,1 the fluorinated pyrimidine 5-fluorouracil (5-FU) remains the single most important chemotherapeutic agent in the treatment of colorectal cancer. Despite over four decades of extensive clinical use, significant controversy still exists regarding the optimal dose and schedule of administration for this foundational agent, however.
